New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
15:32 EDTTWER, FST, REN, JOBS, MR, ICPT, CZR, GSAT, OPK, NUAN, TRAK, CIM, RAX, VTRNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Ventas (VTR), consensus $1.09; Nuance Communications (NUAN), consensus 27c; Intercept Pharmaceuticals (ICPT), consensus (12c); Rackspace Hosting (RAX), consensus 16c; Opko Health (OPK), consensus (9c); Mindray Medical (MR), consensus 54c; Chimera Investment (CIM), consensus 9c; Globalstar (GSAT), one estimate (4c); 51job (JOBS), consensus 32c; Dealertrack Technologies (TRAK), consensus 373c; Caesars Entertainment (CZR), consensus ($1.19); Towerstream (TWER), consensus (10c); Resolute Energy (REN), consensus 1c; Forest Oil (FST), consensus (2c).
News For VTR;NUAN;ICPT;RAX;OPK;MR;CIM;GSAT;JOBS;TRAK;CZR;TWER;REN;FST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
10:54 EDTOPKOPKO Health receives FDA approval for VARUBI
Subscribe for More Information
10:34 EDTOPKLadenburg reiterates Buy on OPKO after Varubi approval
Subscribe for More Information
08:50 EDTOPKOPKO Health rises after TESARO gets FDA approval for VARUBI
Shares of both OPKO Health (OPK) and TESARO (TSRO) are higher in pre-market trading after the latter announced earlier that the FDA has approved VARUBI in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. An intravenous formulation of rolapitant is also being developed. TESARO licensed exclusive rights for the development, manufacture, commercialization and distribution of VARUBI from OPKO Health. In pre-market trading, TESARO shares rose 4.3% to $53.90, while OPKO shares gained 4.5% to $11.30.
August 31, 2015
07:11 EDTICPTIntercept announces NDA for OCA accepted for review by FDA
Subscribe for More Information
August 28, 2015
09:34 EDTCZRNevada reports July statewide gaming win down 0.96% to $922.89M
Subscribe for More Information
06:50 EDTCZRJudge says Caesars, bondholders should prepare for trial, WSJ reports
A federal judge said that Caesars Entertainment and a group of bondholders should prepare for hearings in a suit over Caesars' guarantees of billions of dollars of debt, the Wall Street Journal reports. Judge Shira A. Scheindlin of the U.S. District Court in Manhattan said that there is a discrepancy as to whether a series of asset moving deals last year constituted an out-court debt reorganization that proved harmful to the holders of over $6B in bond debt issued by Caesars, the report says. Reference Link
August 27, 2015
10:57 EDTCZRCaesars bondholders denied immediate ruling by judge, Bloomberg reports
Subscribe for More Information
August 26, 2015
09:15 EDTOPKOPKO CEO Frost issues letter to shareholders on Bio-Reference deal
OPKO Health (OPK) chairman and CEO Phillip Frost released a letter to shareholders regarding the recently announced acquisition of Bio-Reference Laboratories (BRLI). "The strategy behind the recent Bio-Reference acquisition is twofold. First, it is a business whose revenues and profits have grown consistently since its launch by Dr. Marc Grodman in the 1980's, primarily through organic growth, to become the third largest full service reference laboratory in the United States," the letter reads. "It has built a reputation of innovation with recognized franchises in women's health, cancer and, more recently, genetics, helping physicians worldwide to diagnose rare genetic disorders and to identify special features of a patient's genetic material to select more effective chemotherapy. Second, it provides an infrastructure for marketing and sales that reaches approximately 10M patients a year." The letter adds that the 4Kscore test confirms elevated PSA tests have reduced costs by roughly $1B and, if the costs of downstream treatment interventions are also considered, there could be $2.5B additional annual savings to the U.S. health care system. "Among the many compelling reasons for the acquisition, we believe Bio-Reference will greatly accelerate the commercial success of the 4Kscore test," the letter continues. "Bio-Reference has the capacity to dramatically increase the number of 4Kscore tests done each day. They provide national marketing and distribution with a large client services group and a large dedicated sales force that already have strong relationships with primary care physicians. Bio-Reference has over 1,200 phlebotomists and 180 blood-draw centers around the country that can facilitate patient access. Finally, Bio-Reference has robust billing operations and a seasoned national reimbursement team that participates in almost every major commercial insurance plan. Bio-Reference has the expertise and extensive infrastructure to help make the 4Kscore test the new standard for identifying aggressive prostate cancer in men with a suspicious PSA." To close the letter, Frost wrote, "Given Bio-Reference's historical seasonal trends, we expect the second half of 2015 to show continuing growth in earnings and profits. We further expect that the contributions of Bio-Reference, FineTech and EirGen, will create positive EBITDA, or earnings before interest, income taxes, depreciation and amortization, for OPKO. Finally, we expect to continue to invest in research and development activities which, if successful, will result in ongoing improvement of our financial performance."
August 24, 2015
18:55 EDTNUANOn The Fly: After Hours Movers
Subscribe for More Information
07:38 EDTCZRCaesars to pay $20M to settle anti-money laundering lapses charges, Reuters says
Caesars Entertainment has agreed to pay $20M to settle claims of anti-money laundering lapses, Reuters reports, citing a source familiar with the matter. The company will also enter into a deferred prosecution agreement with the DOJ, the report says. Reference Link
August 23, 2015
14:49 EDTCZRCaesars reaches restructuring support agreement with first lien bank lenders
Caesars Entertainment and Caesars Entertainment Operating Co. announced they have entered into a bank restructuring support agreement. The agreement, which is effective immediately, "secures the support" of CEOC's largest and most senior creditor constituencies and represents a "key milestone" in Caesars Entertainment and CEOC's efforts to implement a consensual restructuring of CEOC, according to Caesars. "CEOC's restructuring is now supported by CEOC's first lien bank lenders and first lien bondholders, which represent the most senior $12B of CEOC's capital structure," said the company. Caesars and CEOC continue to engage in discussions with junior creditors to build additional support for the previously announced second lien restructuring agreement. "However, the senior creditors' support of today's agreement paves the way toward a confirmable plan for the restructuring of CEOC," commented Caesars. The bank RSA is substantially similar to the previously announced bond RSA.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use